A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: JNJ-77242113 Matching Placebo
- Registration Number
- NCT06220604
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 731
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) >=12 at screening and baseline
- Total investigator global assessment (IGA) >=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
- Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib or to any of the excipients or components of the study intervention
- Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description JNJ-77242113 Deucravacitinib Matching Placebo Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24. Placebo Deucravacitinib Matching Placebo Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156. Deucravacitinib Deucravacitinib Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156. Placebo JNJ-77242113 Matching Placebo Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156. Deucravacitinib JNJ-77242113 Matching Placebo Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156. Placebo JNJ-77242113 Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156. JNJ-77242113 JNJ-77242113 Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24. Deucravacitinib JNJ-77242113 Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.
- Primary Outcome Measures
Name Time Method JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16 Baseline and Week 16 Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2 Grade Improvement From Baseline at Week 16 Baseline and Week 16 Percentage of participants achieving an IGA score of 0 or 1 and \>=2 grade improvement from baseline at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
- Secondary Outcome Measures
Name Time Method JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an IGA Score of 0 at Week 16 Week 16 Percentage of participants achieving an IGA Score of 0 at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Weeks 4 and 16 Baseline, Weeks 4 and 16 Percentage of participants achieving PASI 75 response (\>=75% improvement in PASI from baseline) at Weeks 4 and 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 90 Response at Weeks 16 and 24 Baseline, Weeks 16 and 24 Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving >=4 Point Improvement From Baseline in PSSD Itch Score at Weeks 4 and 16 Baseline, Weeks 4 and 16 Percentage of participants achieving \>=4 Point improvement from baseline in PSSD itch score at Weeks 4 and 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving an IGA Score of 0 at Weeks 16 and 24 Weeks 16 and 24 Percentage of participants who achieve an IGA score of 0 at Weeks 16 and 24 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 90 Response at Week 8 Baseline and Week 8 Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 8 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16 Baseline and Week 16 Percentage of participants achieving PASI 100 response (100% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 75 Response at Weeks 16 and 24 Baseline, Weeks 16 and 24 Percentage of participants achieving PASI 75 response (\>=75% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Number of Participants with Adverse Events (AEs) Up to 165 weeks An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Percent Improvement in PASI Score From Baseline at Week 16 Baseline and Week 16 Percent improvement in PASI score from Baseline at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline to Week 16 Baseline and Week 16 Percentage of participants achieving a hf-PGA score of 0 or 1 and at least a 2-grade improvement from baseline to Week 16 will be reported. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3), and severe (4).
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Scalp-specific Investigator Global Assessment (ss-IGA) Score of 0 or 1 and a >=2-grade Improvement From Baseline at Week 16 Baseline and Week 16 Percentage of participants achieving ss-IGA score of 0 or 1 and a \>=2-grade improvement from baseline at Week 16 will be reported. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Symptom and Sign Diary (PSSD) Symptoms Score of 0 at Weeks 8 and 16 Weeks 8 and 16 Percentage of participants achieving PSSD symptoms score of 0 at Weeks 8 and 16 will be reported. The PSSD is a self-administered patient-reported outcome (PRO) instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percent of Participants Achieving Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16 Week 16 Percent of participants achieving f-PGA score of 0 or 1 at Week 16 will be reported. The f-PGA is used to evaluate the current status of a participant's fingernail psoriasis on a scale of 0 to 4 (clear \[0\], minimal \[1\], mild \[2\], moderate \[3\], or severe \[4\]).
JNJ-77242113 and Placebo Group: Change From Baseline in PSSD Sign Score at Week 16 Baseline and Week 16 Change from baseline in PSSD sign score at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 or 1 at Week 16 Week 16 Percentage of participants achieving DLQI total score of 0 or 1 at Week 16 will be reported. The DLQI is a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving DLQI Score of 0 or 1 at Weeks 16 and 24 Weeks 16 and 24 Percentage of participants achieving DLQI score of 0 or 1 at Weeks 16 and 24 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
JNJ-77242113 and Deucravacitinib Group: : Percentage of Participants Achieving an IGA Score of 0 or 1 and >=2 Grade Improvement From Baseline at Weeks 16 and 24 Baseline, Weeks 16 and 24 Percentage of participants who achieve an IGA score of 0 or 1 and \>=2 grade improvement from baseline at Weeks 16 and 24 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 100 Response at Weeks 16 and 24 Weeks 16 and 24 Percentage of participants achieving PASI 100 response (\>=100% improvement in PASI) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Number of Participants with Serious Adverse Events (SAEs) Up to 165 weeks SAEs are any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, or is medically important.
Change From Baseline in Body Surface Area (BSA) at Week 16 Baseline and Week 16 Change from baseline in BSA at Week 16 will be reported. BSA is a commonly used measure of extent of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed (that is, plaque psoriasis).
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and >=2-grade Improvement From Baseline to Week 16 Baseline and Week 16 Percentage of participants achieving a sPGA-G Score of 0 or 1 and \>=2-grade improvement from baseline to Week 16 will be reported. The sPGA-G is a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5).
JNJ-77242113 and Deucravacitinib Group: Percentage of Participants With PSSD Symptom Score of 0 at Week 16 Week 16 Percentage of participants achieving PSSD symptom score 0 at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
Change from Baseline in PASI Score at Week 16 Baseline and Week 16 Change from baseline in PASI score at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas are assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16 Baseline and Week 16 Percent change from baseline in mNAPSI score at Week 16 will be reported. The mNAPSI is an index used for assessing and grading the severity of nail psoriasis. Each of the participant's 10 fingernails are evaluated for 7 features. The first 3 features are each scored from 0 to 3 in severity and are (1) onycholysis and oil-drop dyschromia, (2) pitting, and (3) nail plate crumbling. The next 4 features are scored 0 - absent or 1 - present and are (1) leukonychia, (2) splinter hemorrhages, (3) nail bed hyperkeratosis, and (4) red spots in the lunula. The score ranges from 0 to 13 per nail and 0 to 130 for all fingernails.
JNJ-77242113 and Placebo Group: Percentage of Participants With PSSD Sign Score of 0 at Week 16 Week 16 Percentage of participants with PSSD sign score of 0 at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 Week 16 Percentage of participants achieving GenPs-SFQ Item 2 score of 0 or 1 at Week 16 will be reported. The GenPs-SFQ is a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (never \[0\], rarely \[1\], sometimes \[2\], often \[3\], or always \[4\]).
JNJ-77242113 and Placebo Group: Change From Baseline in Total DLQI Score at Week 16 Baseline and Week 16 Change from baseline in total DLQI score at Week 16 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
Percentage of Participants Who Achieve PASI 90 Response After Week 24 Among PASI 90 Non-responders to Deucravacitinib at Week 24 Baseline and from Week 24 through Week 156 Percentage of participants who achieve PASI 90 response (\>=90% improvement in PASI) after Week 24 among PASI 90 non-responders to deucravacitinib at Week 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PSSD Symptom Score of 0 at Week 24 Week 24 Percentage of participants achieving PSSD symptom score of 0 at Week 24 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Change From Baseline in PSSD Symptom Score at Week 16 Baseline and Week 16 Change from baseline in PSSD symptom score at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
JNJ-77242113 and Placebo Group: Change from Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16 Baseline and Week 16 Change from baseline in domain scores of the PROMIS-29 score at Week 16 will be reported. The PROMIS-29 is a 29-item generic HRQoL survey, assessing each of the 7 PROMIS domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. The questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.
Percentage of Participants Achieving IGA Score of 0 or 1 after Week 24, Among Participants with IGA score >=2 at Week 24 in the Deucravacitinib Group From Week 24 through Week 156 Percentage of participants achieving IGA score of 0 or 1 after Week 24, among participants with IGA score \>=2 at Week 24 in the deucravacitinib group will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieve PASI 75 Response After Week 24 Among PASI 75 Non-responders to Deucravacitinib at Week 24 Baseline and from Week 24 through Week 156 Percentage of participants who achieve PASI 75 response (\>=75% improvement in PASI) after Week 24 among PASI 75 Non-responders to deucravacitinib at Week 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Trial Locations
- Locations (126)
Universitatsmedizin der Johannes Gutenberg Universitat Mainz
🇩🇪Mainz, Germany
WroMedica I Bielicka A Strzalkowska s c
🇵🇱Wroclaw, Poland
Essential Medical Research
🇺🇸Tulsa, Oklahoma, United States
Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
🇩🇪Dresden, Germany
Hautzentrum Dulmen
🇩🇪Dulmen, Germany
Privatpraxis Dr. Hilton & Partner
🇩🇪Dusseldorf, Germany
Derma-Study-Center Friedrichshafen GmbH
🇩🇪Friedrichshafen, Germany
Eurofins bioskin GmbH
🇩🇪Hamburg, Germany
Universitaetsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Hautarztpraxis
🇩🇪Witten, Germany
Hautmedizin Saar
🇩🇪Merzig, Germany
Universitaetsklinikum Muenster
🇩🇪Muenster, Germany
Klinikum Oldenburg
🇩🇪Oldenburg, Germany
CentroDerm GmbH
🇩🇪Wuppertal, Germany
Uno Medical Trials Ltd.
🇭🇺Budapest, Hungary
Bugat Pal Korhaz
🇭🇺Gyongyos, Hungary
Synexus Magyarorszag Kft
🇭🇺Zalaegerszeg, Hungary
Bacs Kiskun Varmegyei Oktatokorhaz
🇭🇺Kecskemet, Hungary
Fundacao do ABC Centro Universitario FMABC
🇧🇷Santo Andre, Brazil
Dr. Chih ho Hong Medical
🇨🇦Surrey, British Columbia, Canada
Alliance Dermatology and MOHS Center P C
🇺🇸Phoenix, Arizona, United States
California Dermatology & Clinical Research Institute
🇺🇸Encinitas, California, United States
T Joseph Raoof Md Inc
🇺🇸Encino, California, United States
UCSF Fresno
🇺🇸Fresno, California, United States
University of California Los Angeles
🇺🇸Los Angeles, California, United States
Wallace Medical Group, Inc
🇺🇸Los Angeles, California, United States
Dermatologist Medical Group of North County, Inc.
🇺🇸Oceanside, California, United States
Miami Dermatology And Laser Institute
🇺🇸Miami, Florida, United States
Bioclinical Research Alliance Inc.
🇺🇸Miami, Florida, United States
Forcare Clinical Research Inc
🇺🇸Tampa, Florida, United States
Southeast Dermatology Specialists
🇺🇸Douglasville, Georgia, United States
Arlington Dermatology
🇺🇸Rolling Meadows, Illinois, United States
Skin Sciences, PLLC
🇺🇸Louisville, Kentucky, United States
Qualmedica Research
🇺🇸Owensboro, Kentucky, United States
DermAssociates, PC
🇺🇸Rockville, Maryland, United States
Metro Boston Clinical Partners
🇺🇸Brighton, Massachusetts, United States
ActivMed Practices and Research
🇺🇸Methuen, Massachusetts, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Great Lakes Research Group
🇺🇸Bay City, Michigan, United States
The Derm Institute of West Michigan
🇺🇸Caledonia, Michigan, United States
Hamzavi Dermatology
🇺🇸Canton, Michigan, United States
Somerset Skin Centre
🇺🇸Troy, Michigan, United States
Cleaver Dermatology
🇺🇸Kirksville, Missouri, United States
Bexley dermatology research
🇺🇸Bexley, Ohio, United States
Oregon Dermatology & Research Center
🇺🇸Portland, Oregon, United States
Paddington Testing Co, Inc.
🇺🇸Philadelphia, Pennsylvania, United States
Clinical Research Center of the Carolinas LLC
🇺🇸Charleston, South Carolina, United States
Palmetto Clinical Trial Services, LLC
🇺🇸Greenville, South Carolina, United States
Arlington Research Center, Inc.
🇺🇸Arlington, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Dermatology Clinical Research Center of San Antonio
🇺🇸San Antonio, Texas, United States
Center for Clinical Studies
🇺🇸Webster, Texas, United States
Cope Family Medicine - Ogden Clinic
🇺🇸Bountiful, Utah, United States
Springville Dermatology CCT Research
🇺🇸Springville, Utah, United States
Kalo Clinical Research
🇺🇸West Valley City, Utah, United States
Virginia Dermatology Skin Cancer Center Pllc
🇺🇸Norfolk, Virginia, United States
The Skin Centre
🇦🇺Benowa, Australia
Monash Medical Centre
🇦🇺Clayton, Australia
Premier Specialists
🇦🇺Kogarah, Australia
The Alfred Hospital
🇦🇺Melbourne, Australia
ISHI dermatology
🇦🇺Mitcham, Australia
Royal Melbourne Hospital
🇦🇺Parkville, Australia
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
🇧🇷Botucatu, Brazil
Chronos Clinica Medica LTDA Chronos Pesquisa Clinica
🇧🇷Brasilia, Brazil
Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP
🇧🇷Ribeirao Preto, Brazil
Fundacao Faculdade Regional De Medicina S Jose Rio Preto Hospital De Base
🇧🇷Sao Jose do Rio Preto, Brazil
Hospital Das Clinicas Da Faculdade De Medicina Da USP
🇧🇷Sao Paulo, Brazil
Wiseman Dermatology Research Inc.
🇨🇦Winnipeg, Manitoba, Canada
Lovegrove Dermatology
🇨🇦London, Ontario, Canada
Lynderm Research Inc.
🇨🇦Markham, Ontario, Canada
DermEdge Research
🇨🇦Mississauga, Ontario, Canada
Skin Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
North York Research Inc
🇨🇦Toronto, Ontario, Canada
Toronto Research Centre
🇨🇦Toronto, Ontario, Canada
XLR8 Medical Research
🇨🇦Windsor, Ontario, Canada
Innovaderm Research Inc.
🇨🇦Montreal, Quebec, Canada
Centre De Recherche Dermatologique Du Quebec Metropolitain
🇨🇦Quebec, Canada
Hautarztpraxis Dr. Mihaescu
🇩🇪Augsburg, Germany
Fachklinik Bad Bentheim
🇩🇪Bad Bentheim, Germany
CRS Clinical Research Services Berlin GmbH
🇩🇪Berlin, Germany
Niesmann & Othlinghaus GbR
🇩🇪Bochum, Germany
Klinikum Darmstadt GmbH - Hautklinik
🇩🇪Darmstadt, Germany
Korea University Ansan Hospital
🇰🇷Ansan-si, Korea, Republic of
Hallym University Sacred Heart Hospital
🇰🇷Anyang-si, Korea, Republic of
The Catholic University of Korea Bucheon St Mary s Hospital
🇰🇷Bucheon si, Korea, Republic of
Chosun university hospital
🇰🇷Gwangju, Korea, Republic of
CHA Bundang Medical Center, CHA University
🇰🇷Seongnam, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Renew Clinic
🇵🇱Bialystok, Poland
Care Clinic
🇵🇱Katowice, Poland
Centrum Medyczne Angelius Provita
🇵🇱Katowice, Poland
Prywatny Gabinet Dermatologiczny Elzbieta Klujszo
🇵🇱Kielce, Poland
SGD s.c.
🇵🇱Krakow, Poland
Krakowskie Centrum Badan Klinicznych
🇵🇱Krakow, Poland
Jagiellonskie Centrum Innowacji
🇵🇱Krakow, Poland
Diamond Clinic
🇵🇱Krakow, Poland
Etyka Osrodek Badan Klinicznych
🇵🇱Olsztyn, Poland
Royalderm Agnieszka Nawrocka
🇵🇱Warsaw, Poland
Carpe Diem Centrum Medycyny Estetycznej
🇵🇱Warszawa, Poland
Synexus Polska Sp z o o Oddzial w Warszawie
🇵🇱Warszawa, Poland
Cabinet Medical Dermato-Venerologie
🇷🇴Cluj-Napoca, Romania
Centrul Medical Vitaplus
🇷🇴Craiova, Romania
Spitalul Clinic Judetean de Urgenta
🇷🇴Craiova, Romania
Sc Iasiprest Srl
🇷🇴Iasi, Romania
Spitalul Clinic Judetean de Urgenta Bihor
🇷🇴Oradea, Romania
Spitalul Clinic Judetean Mures
🇷🇴Targu Mures, Romania
New Derm Clinic
🇷🇴Timisoara, Romania
Hosp. Univ. Fundacion Alcorcon
🇪🇸Alcorcon, Spain
Hosp. Univ. Germans Trias I Pujol
🇪🇸Badalona, Spain
Hosp Clinic de Barcelona
🇪🇸Barcelona, Spain
Hosp. de Manises
🇪🇸Manises, Spain
Hosp Clinico Univ de Salamanca
🇪🇸Salamanca, Spain
Clinica Gaias
🇪🇸Santiago de Compostela, Spain
Hosp. Clinico Univ. de Santiago
🇪🇸Santiago de Compostela, Spain
Hosp. Virgen Macarena
🇪🇸Sevilla, Spain
Hosp. Ntra. Sra. de Valme
🇪🇸Sevilla, Spain
Hosp. de La Marina Baixa
🇪🇸Villajoyosa, Spain
Hosp. Clinico Univ. Lozano Blesa
🇪🇸Zaragoza, Spain
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Kaohsiung Veterans General Hospital
🇨🇳Kaohsiung, Taiwan
Chung Shan Medical University Hospital
🇨🇳Taichung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Taipei Medical University
🇨🇳Taipei, Taiwan
Taipei Municipal Wanfang Hospital
🇨🇳Taipei, Taiwan